Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

Marketing 52

Marketing Compound Screening Assay Development Drugs 52

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246

Drug Discovery World

AUGUST 15, 2023

Unexpected late-stage failures in drug development are, of course, the costliest. A more recent analysis has illustrated how both assay validity and reproducibility correlate across a population of simulated screening and disease models 2. 2012) Nature Reviews Drug Discovery, 11: 191–200. Scannell & Bosley.

Drugs 130

Drugs Clinical Pharmacology Disease Engineering 130